Skip to main content
Novartis' ALL candidate gets NICE recommendation

Novartis' Kymriah, or tisagenlecleucel, was recommended by the UK's National Institute for Health and Care Excellence for use in patients younger than 25 who have relapsed or refractory B-cell acute lymphoblastic leukemia. The drug will be funded by the National Health Service through the Cancer Drugs Fund.

Full Story: